stockrow
Friday 6 November 2026
Export VCYT’s income statement to Excel — free account
Veracyte, Inc.
VCYT Healthcare Diagnostics & Research
Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024.
- Revenue
- +15.1%
- EPS
- +62.5%
- Free cash flow
- −9.63%
Quarter to September 2026, against a year earlier
24.86
0.86
+3.58%
Follow VCYT
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
8 | 8 | 6 | 5 | 4 | 3 | 5 | 6 | 4 | 5 |
P/E ratio |
50.12 | 123.75 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
21.08 | 14.82 | 16.66 | 12.40 | 18.10 | 43.59 | 21.36 | 5.11 | (0.11) | 1.18 |
P/S ratio |
6.40 | 6.79 | 5.51 | 5.47 | 12.74 | 22.18 | 10.70 | 5.06 | 3.17 | 3.48 |
P/FCF ratio |
26.13 | 47.47 | 58.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
15.66 | 10.40 | 14.92 | 13.61 | 12.15 | 14.93 | 7.80 | (0.95) | (6.58) | (2.19) |
P/Operating CF |
62.92 | 123.50 | 127.99 | 166.32 | 331.17 | 1,152.37 | 719.65 | (379.86) | (39.20) | (53.48) |
Beneish M-Score |
(2.66) | (2.56) | (3.05) | (2.44) | (0.28) | (2.84) | (1.50) | (2.82) | (2.56) | (1.88) |
P/B ratio |
2.53 | 2.58 | 1.91 | 1.51 | 2.55 | 6.19 | 5.38 | 5.84 | 6.12 | 3.80 |
Price to Tangible BV |
7.30 | 9.24 | 7.88 | 7.93 | 15.05 | 7.27 | 7.50 | 6.98 | 9.87 | 5.10 |
EV/Sales |
5.60 | 6.15 | 4.92 | 4.87 | 11.95 | 19.23 | 9.40 | 4.49 | 3.07 | 2.98 |
EV/EBITDA |
38.17 | 69.86 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
21.26 | 36.51 | 40.17 | 191.64 | (82.92) | (232.62) | (349.92) | (30.54) | (9.23) | (6.93) |
EV/FCF |
22.88 | 42.97 | 51.84 | (1,424.06) | (70.87) | (180.03) | (189.60) | (26.83) | (8.75) | (6.02) |
Quick Ratio |
7.63 | 4.27 | 4.19 | 3.56 | 3.41 | 21.92 | 10.23 | 6.98 | 3.87 | 5.90 |
Current Ratio |
8.15 | 4.73 | 4.66 | 3.97 | 3.79 | 22.39 | 10.74 | 7.42 | 4.48 | 6.38 |
Net Debt/EBITDA |
(5.44) | (7.37) | 3.66 | 11.80 | 2.83 | 12.63 | 14.43 | 2.88 | 0.39 | 1.30 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.09% | 0.61% | 0.62% | 20.96% | 32.09% | 25.26% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.32 | 0.68 | 0.43 |
Asset Turnover |
0.38 | 0.37 | 0.32 | 0.25 | 0.27 | 0.32 | 0.61 | 0.92 | 0.80 | 0.74 |
Operating CF/Net income |
2.05 | 3.11 | (0.59) | (0.21) | 0.42 | 0.28 | 0.26 | 0.59 | 0.77 | 0.89 |
Capex/Depreciation |
(0.53) | (0.49) | (0.37) | (0.33) | (0.27) | (0.36) | (0.65) | (0.47) | (0.30) | (1.54) |
Interest Coverage |
— | — | — | (20.83) | (606.69) | (154.54) | (22.34) | (11.33) | (5.37) | (10.45) |
| 5.34% | 2.17% | (7.02%) | (3.37%) | (9.96%) | (10.57%) | (7.89%) | (39.32%) | (64.05%) | (56.59%) | |
| 4.90% | 2.00% | (6.55%) | (3.12%) | (9.19%) | (9.53%) | (6.37%) | (23.08%) | (34.50%) | (35.58%) | |
ROIC |
4.03% | 1.14% | (6.48%) | (2.86%) | (5.56%) | (29.62%) | (11.55%) | (51.39%) | (58.03%) | (69.89%) |
Return on Tangible Assets |
14.72% | 7.62% | (30.37%) | (17.95%) | (38.94%) | (9.49%) | (7.03%) | (24.77%) | (60.10%) | (42.62%) |
Average Days of Receivables |
31.52 | 38.10 | 40.82 | 54.18 | 68.94 | 57.36 | 58.61 | 52.24 | 64.51 | 49.10 |
Research and Development Expense of Revenue |
13.69% | 15.54% | 15.87% | 13.69% | 13.60% | 14.64% | 12.34% | 16.11% | 19.29% | 23.54% |
Selling, General and Administrative Expense of Revenue |
40.79% | 46.22% | 51.99% | 57.58% | 82.54% | 75.86% | 68.72% | 70.95% | 76.92% | 79.95% |
Intangible Assets out of Total Assets |
0.61 | 0.65 | 0.71 | 0.75 | 0.77 | 0.14 | 0.25 | 0.11 | 0.18 | 0.15 |
Share Based Compensation of Revenue |
8.43% | 8.13% | 9.18% | 9.02% | 10.26% | 11.06% | 8.15% | 6.48% | 9.20% | 9.80% |
Graham Net Nets |
0.12 | 0.08 | 0.11 | 0.10 | 0.05 | 0.13 | 0.12 | 0.12 | 0.05 | 0.14 |
Graham Number |
17.75 | 10.52 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
2.00% | 0.81% | (3.76%) | (2.21%) | (2.77%) | (1.39%) | (0.95%) | (5.17%) | (13.54%) | (14.01%) |
Free Cash Flow Yield |
3.83% | 2.11% | 1.72% | (0.06%) | (1.32%) | (0.48%) | (0.46%) | (3.31%) | (11.07%) | (14.22%) |
Revenue per Share |
6.58 | 5.83 | 4.97 | 4.14 | 3.23 | 2.21 | 2.61 | 2.49 | 2.12 | 2.26 |
Operating CF per Share |
1.73 | 0.98 | 0.61 | 0.11 | (0.47) | (0.18) | (0.07) | (0.37) | (0.70) | (0.97) |
Capex per Share |
(0.12) | (0.15) | (0.14) | (0.12) | (0.08) | (0.05) | (0.06) | (0.05) | (0.04) | (0.15) |
Free Cash Flow per Share |
1.61 | 0.83 | 0.47 | (0.01) | (0.54) | (0.24) | (0.13) | (0.42) | (0.74) | (1.12) |
Cash per Share |
5.25 | 3.78 | 2.98 | 2.50 | 2.61 | 6.56 | 3.45 | 2.11 | 1.00 | 2.06 |
Shareholders Equity per Share |
16.66 | 15.38 | 14.37 | 15.03 | 16.15 | 7.91 | 5.19 | 2.15 | 1.10 | 2.07 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
16.66 | 15.38 | 14.37 | 15.03 | 16.15 | 7.91 | 5.19 | 2.15 | 1.10 | 2.07 |
Free Cash Flow |
126.63 | 63.81 | 34.26 | (1.01) | (37.00) | (12.55) | (5.96) | (15.39) | (25.23) | (32.19) |
Working Capital |
428.44 | 293.63 | 224.38 | 186.02 | 178.95 | 358.90 | 170.22 | 83.89 | 41.90 | 62.09 |
Capital Expenditures |
(9.68) | (11.29) | (9.96) | (8.55) | (5.38) | (2.84) | (2.73) | (1.87) | (1.31) | (4.21) |
Net Current Asset Value |
391.93 | 248.20 | 214.82 | 167.41 | 151.79 | 339.75 | 151.93 | 56.07 | 12.48 | 32.17 |
EV/EBIT |
50.15 | 169.84 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.02 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.06 |
Price to Operating Income |
57.26 | 187.64 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.82 | 1.01 | 1.30 | 1.46 | 1.30 | 0.88 | 0.47 | 0.44 | 0.45 | 0.24 |
Cash ROIC |
7.35% | 4.35% | 2.72% | (0.08%) | (2.90%) | (1.62%) | (1.49%) | (8.41%) | (26.18%) | (22.29%) |
Accounts Receivable Turnover |
11.34 | 10.26 | 8.56 | 6.94 | 7.33 | 6.22 | 7.41 | 7.11 | 6.70 | 10.62 |
Accounts Payable Turnover |
23.38 | 13.68 | 10.57 | 9.96 | 9.61 | 15.23 | 15.08 | 10.39 | 8.98 | 6.78 |
Inventory Turnover |
7.31 | 7.79 | 8.64 | 9.47 | 9.37 | 7.23 | 7.16 | 7.58 | 6.41 | 7.03 |
Average Days of Payables |
10.84 | 21.35 | 35.96 | 35.97 | 60.64 | 27.44 | 23.27 | 27.76 | 49.88 | 34.75 |
Days of Inventory on Hand |
48.50 | 53.78 | 44.81 | 43.17 | 55.07 | 41.00 | 68.02 | 37.54 | 68.92 | 49.81 |
Average Receivables |
45.59 | 43.45 | 42.20 | 42.74 | 29.96 | 18.90 | 16.25 | 12.94 | 10.74 | 6.13 |
Average Payables |
6.61 | 10.79 | 12.43 | 12.14 | 7.74 | 2.72 | 2.42 | 3.18 | 3.14 | 3.75 |
Average Inventory |
21.15 | 18.94 | 15.21 | 12.76 | 7.94 | 5.73 | 5.10 | 4.36 | 4.40 | 3.62 |
Average Assets |
1,353.03 | 1,207.47 | 1,135.66 | 1,172.12 | 822.49 | 366.19 | 197.93 | 99.65 | 89.85 | 88.14 |
Average Common Equity |
1,242.77 | 1,110.03 | 1,059.65 | 1,085.86 | 758.87 | 330.34 | 159.61 | 58.49 | 48.40 | 55.42 |
Columns are period end dates · fundamentals updated 5 Nov 2026